Clinical Research Directory
Browse clinical research sites, groups, and studies.
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
Sponsor: University of Wisconsin, Madison
Summary
This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-04
Completion Date
2028-02
Last Updated
2026-02-24
Healthy Volunteers
Yes
Interventions
Psilocybin
IV administration, infusion of 3.2 mg psilocybin over 10 minutes, followed by an additional 0.8 mg infused over the following 20 minutes
Saline Placebo
IV administration, placebo will be 20 mL of saline drawn up aseptically into the same sized (30 mL) syringe as is used for the active drug.
Clonidine
0.2 mg of clonidine will be taken by mouth by all participants 60 minutes prior to the initial infusion on Dosing Night
Locations (1)
University of Wisconsin
Madison, Wisconsin, United States